Frontiers in Genetics,
Год журнала:
2019,
Номер
10
Опубликована: Май 16, 2019
As
FDA
approved
small
RNA
drugs
start
to
enter
clinical
medicine,
ongoing
studies
for
the
microRNA
(miRNA)
class
of
RNAs
expand
its
preclinical
and
research
applications.
A
growing
number
reports
suggest
a
significant
utility
miRNAs
as
biomarkers
pathogenic
conditions,
modulators
drug
resistance,
and/or
medical
intervention
in
almost
all
human
health
conditions.
The
pleiotropic
nature
this
non
protein-coding
make
them
particularly
attractive
targets
diseases
with
multifactorial
origin
no
current
effective
treatments.
candidate
begin
proceed
toward
initiation
completion
potential
phase
3
4
trials
future,
landscape
both
diagnostic
interventional
medicine
will
arguably
continue
evolve.
In
mini-review,
we
discuss
miRNA
discovery
development
their
status
trials.
Journal of Experimental & Clinical Cancer Research,
Год журнала:
2019,
Номер
38(1)
Опубликована: Фев. 18, 2019
PD-1/PD-L1
checkpoint
blockades
have
achieved
significant
progress
in
several
kinds
of
tumours.
Pembrolizumab,
which
targets
PD-1,
has
been
approved
as
a
first-line
treatment
for
advanced
non-small
cell
lung
cancer
(NSCLC)
patients
with
positive
PD-L1
expression.
However,
not
breakthroughs
treating
glioblastoma
because
low
immunogenic
response
and
an
immunosuppressive
microenvironment
caused
by
the
precise
crosstalk
between
cytokines
immune
cells.
A
phase
III
clinical
trial,
Checkmate
143,
reported
that
nivolumab,
did
demonstrate
survival
benefits
compared
bavacizumab
recurrent
patients.
Thus,
combination
blockade
RT,
TMZ,
antibodies
targeting
other
inhibitory
or
stimulatory
molecules,
targeted
therapy,
vaccines
may
be
appealing
solution
aimed
at
achieving
optimal
benefit.
There
are
many
ongoing
trials
exploring
efficacy
various
approaches
based
on
primary
Many
challenges
need
to
overcome,
including
identification
discrepancies
different
genomic
subtypes
their
blockades,
selection
versus
glioblastoma,
sequence
therapy.
In
this
review,
we
describe
molecular
characteristics
tumour
(TME),
candidate
biomarkers
glioblastoma.
International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(19), С. 11502 - 11502
Опубликована: Сен. 29, 2022
microRNAs
are
small
non-coding
RNAs
that
regulate
several
genes
post-transcriptionally
by
complementarity
pairing.
Since
discovery,
they
have
been
reported
to
be
involved
in
a
variety
of
biological
functions
and
pathologies
including
cancer.
In
cancer,
can
act
as
tumor
suppressor
or
oncomiR
depending
on
the
cell
type.
Studies
shown
miRNA-based
therapy,
either
inhibiting
an
inducing
suppressor,
is
effective
cancer
treatment.
This
review
focusses
role
miRNA
therapeutic
approaches
with
miRNAs
how
effectively
delivered
into
system.
We
also
summarized
patents
clinical
trials
progress
for
therapy.
Glioblastoma
(GBM)
is
a
central
nervous
system
tumor
with
poor
prognosis
due
to
the
rapid
development
of
resistance
mono
chemotherapy
and
brain
targeted
delivery.
Chemoimmunotherapy
(CIT)
combines
drugs
activators
innate
immunity
that
hold
great
promise
for
GBM
synergistic
therapy.
Herein,
we
chose
temozolomide,
TMZ,
epigenetic
bromodomain
inhibitor,
OTX015,
further
co-encapsulated
them
within
our
well-established
erythrocyte
membrane
camouflaged
nanoparticle
yield
ApoE
peptide
decorated
biomimetic
nanomedicine
(ABNM@TMZ/OTX).
Our
nanoplatform
successfully
addressed
limitations
in
brain-targeted
drug
co-delivery,
simultaneously
achieved
multidimensional
enhanced
CIT.
In
mice
bearing
orthotopic
GL261
GBM,
treatment
ABNM@TMZ/OTX
resulted
marked
inhibition
greatly
extended
survival
time
little
side
effects.
The
pronounced
efficacy
can
be
ascribed
three
key
factors:
(i)
improved
nanoparticle-mediated
targeting
delivery
therapeutic
agents
by
blood
circulation
blood-brain
barrier
penetration;
(ii)
inhibited
cellular
DNA
repair
TMZ
sensitivity
cells;
(iii)
anti-tumor
immune
responses
inducing
immunogenic
cell
death
inhibiting
PD-1/PD-L1
conjugation
leading
expression
CD4
Nature Communications,
Год журнала:
2022,
Номер
13(1)
Опубликована: Ноя. 11, 2022
Abstract
Glioblastoma
multiforme
(GBM)
is
one
of
the
most
fatal
malignancies
due
to
existence
blood-brain
barrier
(BBB)
and
difficulty
maintain
an
effective
drug
accumulation
in
deep
GBM
lesions.
Here
we
present
a
biomimetic
nanogel
system
that
can
be
precisely
activated
by
near
infrared
(NIR)
irradiation
achieve
BBB
crossing
tumor
penetration
drugs.
Synthesized
crosslinking
pullulan
poly(deca-4,6-diynedioic
acid)
(PDDA)
loaded
with
temozolomide
indocyanine
green
(ICG),
nanogels
are
inert
endogenous
oxidative
conditions
but
selectively
disintegrated
ICG-generated
reactive
oxygen
species
upon
NIR
irradiation.
Camouflaging
apolipoprotein
E
peptide-decorated
erythrocyte
membrane
further
allows
prolonged
blood
circulation
active
targeting.
The
controlled
on
lesions
excites
ICG
deforms
cumulated
trigger
burst
release
for
facilitated
permeation
infiltration
into
distal
cells.
These
NIR-activatable
suppress
growth
orthotopic
stem
cells-bearing
mouse
models
significantly
extended
survival.
Frontiers in Molecular Biosciences,
Год журнала:
2020,
Номер
7
Опубликована: Сен. 8, 2020
Glioblastoma
(GBM)
is
highly
invasive
and
the
most
deadly
brain
tumor
in
adults,
characterized
by
substantial
inter-tumor
intra-tumor
heterogeneity,
short
survival,
lack
of
effective
treatment.
Current
molecular
analysis
tends
to
apply
multiple
data
from
transcription,
genetic
alterations
DNA
methylation
predict
patient
prognosis
guide
therapy.
Proneural,
neural,
classical,
mesenchymal
are
distinct
GBM
subtypes
classified
which
widely
accepted
used
for
diagnosis,
classification
targeted
treatment,
closely
related
other
based
on
methylation.
In
this
review,
we
summarize
principal
its
advantages
various
aspects,
such
as
supplementary
pathology
prediction,
Cancers,
Год журнала:
2021,
Номер
13(8), С. 1795 - 1795
Опубликована: Апрель 9, 2021
Glioblastoma
(GBM),
the
most
frequent
and
aggressive
glial
tumor,
is
currently
treated
as
first
line
by
Stupp
protocol,
which
combines,
after
surgery,
radiotherapy
chemotherapy.
For
recurrent
GBM,
in
absence
of
standard
treatment
or
available
clinical
trials,
various
protocols
including
cytotoxic
drugs
and/or
bevacizumab
are
applied.
Despite
these
heavy
treatments,
mean
overall
survival
patients
under
18
months.
Many
studies
underway.
Based
on
clinicaltrials.org
conducted
up
to
1
April
2020,
this
review
lists,
not
only
main,
but
all
targeted
therapies
phases
II-IV
257
trials
adults
with
newly
diagnosed
GBMs
for
last
twenty
years.
It
does
involve
immunotherapies
targeting
tumor
cell
metabolism,
that
well
documented
other
reviews.
Without
surprise,
frequently
reported
those
(i)
EGFR
(40
trials),
more
generally
tyrosine
kinase
receptors
(85
trials)
(ii)
VEGF/VEGFR
(75
53
involving
bevacizumab).
But
many
targets
interest.
They
listed
thoroughly
described,
an
one-on-one
basis,
four
sections
related
GBM
stem
cells
pathways,
growth
autonomy
migration,
(iii)
cycle
escape
death,
(iv)
angiogenesis.
Human
glioblastoma
is
the
most
aggressive
type
of
primary
malignant
brain
tumors.
Standard
treatment
includes
surgical
resection
followed
by
radiation
and
chemotherapy
but
it
only
provides
short-term
benefits
prognosis
these
tumors
still
very
poor.
Glioblastomas
contain
a
population
glioma
stem
cells
(GSCs),
with
self-renewal
ability,
which
are
partly
responsible
for
tumor
resistance
to
therapy
recurrence
after
treatments.
The
human
adult
subventricular
zone
contains
astrocyte-like
neural
(NSCs)
that
probably
reminiscent
radial
glia
present
in
embryonic
development.
There
numerous
molecules
involved
biology
NSCs
also
instrumental
These
include
cytoskeletal
proteins,
telomerase,
suppressor
transcription
factors
growth
factors.
Interestingly,
genes
encoding
frequently
mutated
cells.
Indeed,
has
been
recently
shown
potential
cell
origin
driver
mutations
glioblastoma.
In
this
review
we
will
describe
common
features
between
GSCs
NSCs,
discuss
relevance
important
finding
terms
possible
future
therapeutic
strategies.
